Huang Xiaojun Elected Vice President of the 4th Council of WACD and Awarded "the Fifth Fok Ying-Tung Prize"
On September 22, the 2023 Annual Conference of World Association of Chinese Doctors (WACD) and Medical Innovation & Transformation Forum was held. At the meeting, Huang Xiaojun, Director of the National Clinical Research Center for Hematologic Disease and President of Peking University Institute of Hematology, was elected Vice President of the Fourth Council of WACD and awarded " the Fifth Fok Ying-Tung Prize---the World Outstanding Chinese Doctor Award".
Since 2004, Huang Xiaojun's team has been continuously creating and improving multiple key technologies to form a system based on completing the world's largest number of haploidentical transplantation.
By the end of 2021, Peking University People's Hospital (PKUPH) had become the world's largest center for allogeneic and haploidentical transplantation, thus being the preferred option for over 95% of all the transplantation in China, with an overall survival rate of 75% -86% for acute leukemia.
In 2016, the International Society for Blood and Marrow Transplantation officially named the Chinese scientific protocol created by Huang Xiaojun's team as the "Beijing Protocol". At present, the key technologies of the Beijing Protocol have been promoted to more than 10 transplant centers in countries including Italy, Israel, France, and South Korea, covering over 50% of the haploidentical transplantation cases worldwide, becoming the global mainstream protocol for leukemia.
Written by: Wu Zhaoxia
Edited by: LiuXin